|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR:A systematic literature review显示文摘AIM:To review literature on efficacy and safety of octreotide-long-acting repeatable(LAR)used at doses higher than the Food and Drug Administration(FDA)-approved 30 mg/mo for treatment of neuroendocrine tumors(NETs).METHODS:We searched Pub Med and Cochrane Library from 1998-2012,5 conferences(American Society of Clinical Oncology,Endocrine Society,European Neuroendocrine Tumor Society,European Society for Medical Oncology,North American Neuroendocrine Tumor Society)from 2000-2013 using Me SH and keyterms including neuroendocrine tumors,carcinoid tumor,carcinoma,neuroendocrine,and octreotide.Bibliographies of accepted articles were also searched.Two reviewers reviewed titles,abstracts,and full-length articles.Studies that reported data on efficacy and safety of≥30 mg/mo octreotide-LAR for NETs in human subjects,published in any language were included in the review.RESULTS:The search identified 1086 publications,of which 238 underwent full-text review(20 were translated into English);17 were included in the review.Studies varied in designs,subjects,octreotide-LAR regimens,and definition of outcomes.Eleven studies reported use of higher doses to control symptoms and tumor progression,although symptom severity and formal quality-of-life analysis were not quantitatively measured.Ten studies reported efficacy,describing 260 subjects with doses ranging from 40 mg/mo or 30 mg/3 wk up to 120 mg/mo.Eight studies reported expert clinical opinion that supported dose escalation of octreotide-LAR up to 60 mg/mo for symptom control and suggested increased doses may be effective at preventing tumor progression.Eight studies reported safety;there was no evidence of increased toxicity associated with doses of octreotide-LAR>30 mg/mo.CONCLUSION:As reported in this review,octreotide-LAR at doses>30 mg/mo is being prescribed for symptom and tumor control in NET patients.Furthermore,expert clinical opinion provided support for escalation of somatostatin analogs for refractory hormonal symptoms. | Michael S Broder David Beenhouwer Jonathan R Strosberg Maureen P Neary Dasha Cherepanov | 2015 | World Journal of Gastroenterology2015，21，6： | 8 |
| 2 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors显示文摘AIM:To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors(PNETs)and provide consensus treatment recommendations.METHODS:Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs,angiogenesis inhibitors,inhibitors of mammalian target of rapamycinand cytotoxic agents.At this time,there is little data to guide treatment selection and sequence.We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations.Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process.After studying the literature,a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale.Ratings were done both before and after an extended discussion of the evidence.Quantitative measurements of agreement were made and consensus statements developed from the second round ratings.RESULTS:Specialties represented were medical and surgical oncology,interventional radiology,and gastroenterology.Panelists had practiced for a mean of15.5 years(range:6-33).Among 202 rated scenarios,disagreement decreased from 13.2%(26 scenarios)before the face-to-face discussion of evidence to 1%(2)after.In the final ratings,46.5%(94 scenarios)were rated inappropriate,21.8%(44)were uncertain,and30.7%(62)were appropriate.Consensus statements from the scenarios included:(1)it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic;(2)it is appropriate to use everolimus,sunitinib,or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors;and(3)beyond first line,these same agents can be used.In patients with uncontrolled secretory symptoms,octreotide LAR doses can be titrated up to 60 mg every4 wk or up to 40 mg every 3 or 4 wk.CONCLUSION:Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs. | Jonathan R Strosberg George A Fisher Al B Benson Lowell B Anthony Bulent Arslan John F Gibbs Edward Greeno Renuka V Iyer Michelle K Kim William J Maples Philip A Philip Edward M Wolin Dasha Cherepanov Michael S Broder | 2015 | World Journal of Gastroenterology2015，21，8： | 2 |
| 3 | 查看详情显示文摘 | Kiselev E A Cherepanov V A | | 0，，01： | 1 |
| 4 | Analytic description of PS-wave reflection in weakly anisotropic media 显示文摘 | Cherepanov M V Nefedkina T V | 2004 | SEG Technical Program Expanded Abstracts2004，23，1： | 1 |
| 5 | Structural basis for the recognition between HIV-I integrase and trans- criptional coactivator p75 显示文摘 | Cherepanov P Ambrosio AL Rahman S et ol | 2005 | Proc Natl Acad Sci USA2005，102，17： | 1 |
| 6 | pH6 antigen(PsaA protein) of Yersinia pestis, a novel bacterial Fc-receptor显示文摘 | Zav'yalov VP Abramov VM Cherepanov PG | 1996 | FEMS Immunol Med Microbiol1996，14，： | 1 |
| 7 | High-level expression of active HIV-1 integrase from a synthetic gene in human cells显示文摘 | Cherepanov P Pluymers W Claeys A Proost | 2000 | FASEB J2000，14，： | 1 |
| 8 | Analytic description of PS wave reflection in weakly anisotropic media 显示文摘 | Maxim V Cherepanov Tatyana N Nefedkina | 2004 | SEG Technical Program Expanded Abstracts2004，23，1： | 1 |
| 9 | Crack Propagation in Continuous Media 显示文摘 | Cherepanov G P | 1967 | Journal of Applied Mathematics and Mechanics (Translation of PMM)1967，31，： | 1 |
| 10 | HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells显示文摘 | Cherepanov P Maertens G Proost PD | 2003 | J Biol Chem2003，278，： | 1 |
| 11 | Sturgeons sperm quality after 6 years of cryopreservation 显示文摘 | Dzuba B B Kopeika E F Cherepanov V V | 1999 | Journal of Applied Ichthyology1999，15，45： | 1 |
| 12 | Binding of nucleotides by T4 DNA Ligase and T4 RNA Ligase: Optical absorbance and fluorescence studies显示文摘 | Cherepanov A V de Vries S | 2001 | Biophysical Journal2001，81，6： | 1 |
| 13 | S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders显示文摘 | Jordan J. Feld Apurva A. Modi Ramy El–Diwany Yaron Rotman Emmanuel Thomas Golo Ahlenstiel Rachel Titerence Christopher Koh Vera Cherepanov Theo Heller Marc G. Ghany Yoon Park Jay H. Hoofnagle T. Jake Liang | 2011 | Gastroenterology2011，，3： | 1 |
| 14 | Role of Yersi- his Mufine Toxin in survival of Yersinis pestis in the midegut of the flea vector 显示文摘 | Hinnebuseh B J Rudolph A E Cherepanov P | 2002 | Science2002，296，26： | 1 |
| 15 | G-ene disruption in Escherichla coli : TcR and KmR cassettes with the op- tion of flp catalyzed excision of the antibiotic resist ance determinant显示文摘 | Cherepanov P P Wackernagel W | 1995 | Gene1995，158，1： | 1 |
| 16 | Analytic description of PS - wave reflection in weakly anisotropic media显示文摘 | Cherepanov M V Nefedkina T V | 2004 | SEG Technical Program Expanded Abstracts2004，23，1： | 1 |
| 17 | On some general properties of strength criteria显示文摘 | Germanovich L N Cherepanov G P | 1995 | International Journal of Fracture1995，71，1： | 1 |
| 18 | Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75 显示文摘 | Cherepanov P Ambrosio AL Rahman S | 2005 | Proc Natl Acad Sci USA2005，102，17： | 1 |
| 19 | The Problem of Fiber Pullout显示文摘 | CHEREPANOV G P ESPARRAGOZA I E | 1995 | Materials Science and Engineering A1995，203，2： | 1 |
| 20 | Solution structure of the HIV-1 integrase binding domain in LEDGF/p75 显示文摘 | Cherepanov E Sun ZYJ Rahman S | 2005 | Nat Struct Mol Biol2005，12，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员